**Appendix Table E75. Results from studies assessing the ability of Multiplate Analyzer to predict other clinical events in patients with ischemic heart disease**

| **Author, year****UID****Country****Study name** | **Treatment** | **Phenotypic Test Used [index test]** | **Clinical Outcome** | **Outcome Definition** | **Timing of measurement** | **Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP** | **Outcome status (e.g., bleeding or no bleeding)** | **No. with outcome status within phenotype group** | **Comparative metric (OR, RR, HR)** | **95% CI** | **P (between which groups?)****[statistical test]** | **Adjusted?****[YES/NO/NR]****If YES, for what factors?** | **Procedures for multiple comparisons [YES, NO, NR]** | **Comments (e.g., additional data in figures)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sibbing, 200919264241 Sibbing, 201020062919GermanyNR | Clopidogrel: 600 mg LD + 150 mg/day clopidogrel for 3 days + 75 mg/day clopidogrel MD & Aspirin: 500 mg IV LD + 100 mg aspirin (twice per day) MD | MEA | Target lesion reintervention | NR | 30 days | Low Responders (>416 aggregation units\*min) | Target lesion reintervention | 7 (2.2%) | OR=4.02 | 1.53-10.58 | P=0.005(low vs normal responder)[log rank] | NO | NR | Secondary |
|  |  |  |  |  |  | Normal Responders (≤416 aggregation units\*min) |  | 7 (0.5%) |  |  |  |  |  |  |
| Schulz, 201020691843GermanyNR | Clopidogrel 75 mg/d + Aspirin 100 mg/d | MEA by Multiplate analyzer | Clinical restenosis defined as target lesion revascularization (TLR) | repeat PCI of the target lesion or bypass surgery of the target vessel | 1 year | Low responder | Clinical restenosis | 34 (10.9%)  | HR=1.2 | 0.8-1.7 | 0.441(low vs normal)cox proportional hazard model | NO | NR | Primary outcome |
|  |  |  |  |  |  | Normal responder |  | 119 (9.5) |  |  |  |  |  |  |
|  | Clopidogrel 75 mg/d + Aspirin 100 mg/d | MEA by Multiplate analyzer | Clinical restenosis defined as target lesion revascularization (TLR) | repeat PCI of the target lesion or bypass surgery of the target vessel | 1 year | Low responder | Clinical restenosis | 34 (10.9%)  | HR=1 | 0.9-1.1 | 0. 717(low vs normal)Cox regression | YES;chronic occlusions, complex lesions, lesion length, and diameter stenosis before PCI | NR | Secondary outcome |
|  |  |  |  |  |  | Normal responder |  | 119 (9.5) |  |  |  |  |  |  |
| Ivandic, 200919359538GermanyNR | Clopidogrel600mg LD+aspires 0.5g | Aggregometry | Target vessel revascularization | Target vessel revascularization | 30days or later after PCI | Responders (n=163) | Target vessel revascularization | 7 (4.3%) | Relative risk 3.68 | 1.03-13.04 | NR | NR | NR |  |
|  |  |  |  |  |  | Dual nonresponders (n=19) |  | 3 (15.8%) |  |  |  |  |  |  |
| Johnston, 201222465351New ZealandNR | aspirin ≥300 mg at and clopidogrel≥300 mg and/or aspirin (≥75 mg) and clopidogrel (≥75 mg) | MEA | Target vessel revascularization |  | 3 days | High on treatment platelet reactivity >468 AU\*minn=95 | HTPR | 0 | OR (calculated)=1.63 | NR | P=0.81(HTPR vs normal)[Fisher’s exact] | No | NR |  |
|  |  |  |  |  |  | normal platelet reactivity≤468 AU\*minn=155 |  | 0 |  |  |  |  |  |  |
| Sibbing, 201222682553GermanyISAR-REACT 4 | LD: 600 mg of clopidogrel and 500 mg aspirin MD: clopidogrel 75 mg x 12 months and aspirin 100 mg twice daily for an indefinite period | MEA | Target vessel revascularization in pts on Abciximab Plus UFH | Target vessel revascularization | 30 days | high on-treatment platelet reactivity>468 AU\*minn=96 | Target vessel revascularization | 0 | OR(calculated)=0.6 | 0.02-15.2 | P=0.46(HTPR vs normal)[Cox regression] | No | NR |  |
|  |  |  |  |  |  | normal platelet reactivity≤468 AU\*minn=178 |  | 1 |  |  |  |  |  |  |
|  |  |  | Target vessel revascularization in pts on Bivalirudin | Target vessel revascularization | 30 days | high on-treatment platelet reactivity>468 AU\*minn=109 | Target vessel revascularization | 2 | OR(calculated)=8.4 | 0.4-177.5 | P=0.07(HTPR vs normal)[Cox regression] | No | NR |  |
|  |  |  |  |  |  | normal platelet reactivity≤468 AU\*minn=181 |  | 0 |  |  |  |  |  |  |